Margarita Sala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Margarita Sala has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Álvaro Díaz-González
Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases Group, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain
3 shared publications Diana Horta
Servicio de Aparato Digestivo Hospital Universitari Mutua de Terrassa Terrassa Spain
2 shared publications- Jesús Manuel González-Santiago
Department of Gastroenterology, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
2 shared publications - María Del Barrio
Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases Group, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain
2 shared publications - María Varela
Servicio de Digestivo, Sección de Hepatología, Hospital Universitario Central de Asturias, Oviedo, Spain; Universidad de Oviedo, Oviedo, Asturias, Spain; IUOPA, ISPA, FINBA, Oviedo, Spain
2 shared publications - María-Carlota Londoño
Liver Unit, Hospital Clínic Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70713
Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes
Background and Aim: Steatotic liver disease (SLD) is becoming increasingly prevalent, leading to a higher frequency of primary biliary cholangitis (PBC) cases coexisting with SLD. However, data on its impact in patients with PBC remain scarce. The aim is to assess the impact of SLD on treatment response and prognosis in patients with PBC receiving ursodeoxycholic acid (UDCA). Methods: A retrospective, multicenter cohort study including patients diagnosed with PBC enrolled in the Spanish ColHai registry. Results: A total of 469 patients with available data required for the study were included. Among them, 158 (33.7%) had SLD, and 124 (78.5%) met the diagnostic criteria for MASLD. Patients with PBC and SLD had lower baseline levels of alkaline phosphatase and higher liver stiffness at diagnosis. Regarding treatment response, no significant differences were observed across the different response criteria (Paris II, GLOBE, UK‐PBC, deep response and complete normalization). Additionally, the presence of SLD was not associated with UDCA response at 1‐year (Paris II: OR 1.04 [0.69–1.56]; GLOBE: OR 0.91 [0.58–1.44]; deep response: OR 1.08 [0.72–1.63]; complete normalization: OR 0.82 [0.52–1.30]). Baseline SLD was not associated with an increased risk of liver related‐events in either the univariate analysis (HR 1.19, 95% CI 0.71–2.02) or in the different multivariate models evaluated. After inverse probability of treatment weighting (IPTW) using propensity scores, SLD still showed no significant impact on hepatic event development (HR 1.62; 95% CI 0.92–2.83). Conclusion: Although SLD is frequently observed in PBC, it does not appear to adversely affect UDCA response or long‐term hepatic outcomes.
- 5 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70713
Open AccessSteatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes
Background and Aim: Steatotic liver disease (SLD) is becoming increasingly prevalent, leading to a higher frequency of primary biliary cholangitis (PBC) cases coexisting with SLD. However, data on its impact in patients with PBC remain scarce. The aim is to assess the impact of SLD on treatment response and prognosis in patients with PBC receiving ursodeoxycholic acid (UDCA). Methods: A retrospective, multicenter cohort study including patients diagnosed with PBC enrolled in the Spanish ColHai registry. Results: A total of 469 patients with available data required for the study were included. Among them, 158 (33.7%) had SLD, and 124 (78.5%) met the diagnostic criteria for MASLD. Patients with PBC and SLD had lower baseline levels of alkaline phosphatase and higher liver stiffness at diagnosis. Regarding treatment response, no significant differences were observed across the different response criteria (Paris II, GLOBE, UK‐PBC, deep response and complete normalization). Additionally, the presence of SLD was not associated with UDCA response at 1‐year (Paris II: OR 1.04 [0.69–1.56]; GLOBE: OR 0.91 [0.58–1.44]; deep response: OR 1.08 [0.72–1.63]; complete normalization: OR 0.82 [0.52–1.30]). Baseline SLD was not associated with an increased risk of liver related‐events in either the univariate analysis (HR 1.19, 95% CI 0.71–2.02) or in the different multivariate models evaluated. After inverse probability of treatment weighting (IPTW) using propensity scores, SLD still showed no significant impact on hepatic event development (HR 1.62; 95% CI 0.92–2.83). Conclusion: Although SLD is frequently observed in PBC, it does not appear to adversely affect UDCA response or long‐term hepatic outcomes.
- Open Access
- 29 August 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (11) , 101562
Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis
- 29 August 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (11) , 101562
Open AccessIsolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis
- Open Access
- 1 May 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (7) , 101445
Reply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”
- 1 May 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (7) , 101445
Open AccessReply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”
- Open Access
- 30 January 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (5) , 101336
Evolving epidemiology of HCC in Spain
- 30 January 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (5) , 101336
Open AccessEvolving epidemiology of HCC in Spain
- Open Access
- 7 March 2022
- Published by Wiley in Liver International
- Vol. 42 (5) , 1109-1120
Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)
Background & Aims: Alcoholic hepatitis (AH) is associated with a high incidence of infection and mortality. Rifaximin reduces bacterial overgrowth and translocation. We aimed to study whether the administration of rifaximin as an adjuvant treatment to corticosteroids decreases the number of bacterial infections at 90 days in patients with severe AH compared to a control cohort.Methods: This was a multicentre, open, comparative pilot study of the addition of rifaximin (1200 mg/day/90 days) to the standard treatment for severe AH. The results were compared with a carefully matched historical cohort of patients treated with standard therapy and matching by age and model of end‐stage liver disease (MELD). We evaluated bacterial infections, liver‐related complications, mortality and liver function tests after 90 days.Results: Twenty‐one and 42 patients were included in the rifaximin and control groups respectively. No significant baseline differences were found between groups. The mean number of infections per patient was 0.29 and 0.62 in the rifaximin and control groups, respectively (p = .049), with a lower incidence of acute‐on‐chronic liver failure (ACLF) linked to infections within the treatment group. Liver‐related complications were lower within the rifaximin group (0.43 vs. 1.26 complications/patient respectively) (p = .01). Mortality was lower in the treated versus the control groups (14.2% vs. 30.9, p = .15) without significant differences. No serious adverse events were associated with rifaximin treatment.Conclusions: Rifaximin is safe in severe AH with a significant reduction in clinical complications. A lower number of infections and a trend towards a lower ACLF and mortality favours its use in these patients.
- 7 March 2022
- Published by Wiley in Liver International
- Vol. 42 (5) , 1109-1120
Open AccessEffect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)
Background & Aims: Alcoholic hepatitis (AH) is associated with a high incidence of infection and mortality. Rifaximin reduces bacterial overgrowth and translocation. We aimed to study whether the administration of rifaximin as an adjuvant treatment to corticosteroids decreases the number of bacterial infections at 90 days in patients with severe AH compared to a control cohort.Methods: This was a multicentre, open, comparative pilot study of the addition of rifaximin (1200 mg/day/90 days) to the standard treatment for severe AH. The results were compared with a carefully matched historical cohort of patients treated with standard therapy and matching by age and model of end‐stage liver disease (MELD). We evaluated bacterial infections, liver‐related complications, mortality and liver function tests after 90 days.Results: Twenty‐one and 42 patients were included in the rifaximin and control groups respectively. No significant baseline differences were found between groups. The mean number of infections per patient was 0.29 and 0.62 in the rifaximin and control groups, respectively (p = .049), with a lower incidence of acute‐on‐chronic liver failure (ACLF) linked to infections within the treatment group. Liver‐related complications were lower within the rifaximin group (0.43 vs. 1.26 complications/patient respectively) (p = .01). Mortality was lower in the treated versus the control groups (14.2% vs. 30.9, p = .15) without significant differences. No serious adverse events were associated with rifaximin treatment.Conclusions: Rifaximin is safe in severe AH with a significant reduction in clinical complications. A lower number of infections and a trend towards a lower ACLF and mortality favours its use in these patients.
- 1 December 2016
- Published by Elsevier in Gastroenterología y Hepatología (English Edition)
- Vol. 39 (10) , 667-668
Alagille syndrome associated with intestinal atresia
- 1 December 2016
- Published by Elsevier in Gastroenterología y Hepatología (English Edition)
- Vol. 39 (10) , 667-668
Alagille syndrome associated with intestinal atresia